A meta-analysis of the risk of cardiotoxicity, however, showed that by the end of 2000, data from over 20 000 patients had confirmed a highly significant greater risk of myocardial infarction. 15 The authors felt that rofecoxib should have been withdrawn several years earlier.
1
—
—